Resources
Make Hypertension History: A Toolkit for National Hispanic Heritage Month
High blood pressure takes a toll on the Hispanic community. Using the resources in this toolkit, advocates can help raise awareness during Hispanic Heritage Month, September 15–October 15, and expand treatment access for the Hispanic community.
Stopping the Increase in Hypertension
Social media graphic
Societal Costs of Hypertension
Social media graphic
Americans with Hypertension by 2035
Social media graphic
Statistics for People with Hypertension
Social media graphic
Nuevos Tratamientos Contra La Hipertensión
Más de 100 millones de personas en Estados Unidos son hipertensas. Cerca de un tercio de ellas tienen hipertensión no controlada, que se define como aquella en la que, a pesar de tomar tres o más medicamentos, la presión arterial no mejora.
National Organizations Back New Drug Class for Care of Cardiomyopathy Patients
In a big win for heart patients, national guidelines to treat hypertrophic cardiomyopathy now include the first-of-its-kind medication – cardiac myosin inhibitors – as a first-line treatment.
Giving Hypertension Patients New Treatment Options
People with hypertension need options, support and access to the treatment that works best for them.
Hypertrophic Cardiomyopathy: What New Management Guidelines Mean for HCM Patients
Newly updated guidelines, jointly authored by the American College of Cardiology and the American Heart Association, recommend the best ways to diagnose and treat the condition.
Non-Medical Switching Poses a Danger to Medicare Patients
Letter to CMS on the need to monitor non-medical switching protocols to protect patient access.
Understanding Specialty Pharmacies
Patients living with cardiovascular conditions need tailored, quality care. That's where specialty pharmacies come in.
[Webinar] Genetically Targeted Technologies and the MINI Act
Listen to Michael Gibson, MS, MD, Chris Kelly and Ryan Gough as they discuss the need for ongoing innovation and how policy can encourage breakthrough treatments like genetically targeted technologies.